- Home
- ARVN vs BALY Comparison
ARVN vs BALY Comparison
Compare ARVN & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | BALY |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | 11700 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 711.1M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ARVN | BALY |
|---|---|---|
| Price | $7.26 | $13.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 5 |
| Target Price | ★ $13.93 | $9.67 |
| AVG Volume (30 Days) | ★ 646.8K | 89.9K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | 8.37 |
| EPS | ★ 1.70 | N/A |
| Revenue | $262,600,000.00 | ★ $2,436,189,000.00 |
| Revenue This Year | $12.76 | $19.05 |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | $4.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.74 | $8.44 |
| 52 Week High | $14.22 | $19.77 |
Technical Indicators
Market Signals| Indicator | ARVN | BALY |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 60.89 |
| Support Level | $6.74 | $13.23 |
| Resistance Level | $7.74 | $14.22 |
| Average True Range (ATR) | 0.36 | 0.57 |
| MACD | 0.08 | -0.10 |
| Stochastic Oscillator | 51.43 | 69.80 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
About BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, entertainment, and technology company operating across casino, interactive, and lottery markets. It provides physical and interactive gaming experiences, including casino gaming, iGaming, sportsbook, online bingo, free-to-play games, and technology-driven lottery solutions. The company's segments include Casinos & Resorts, which generates maximum revenue and operates casino and resort properties, a horse racetrack, and a golf course; Bally's Intralot B2B, which provides lottery and technology services; Bally's Intralot B2C, which includes interactive gaming and lottery operations, including a UK casino; and North America Interactive, which includes sports betting and iGaming operations in the United States and Canada.